SCHEDULE 13G/A 0001193125-21-038413 0001824633 XXXXXXXX LIVE 6 Common Stock, par value $0.0001 per share 12/31/2025 0001678660 Prelude Therapeutics Inc 74065P101 175 INNOVATION BOULEVARD WILMINGTON DE 19805 Rule 13d-1(d) Vaddi Krishna X1 6745647 0 6745647 0 6745647 N 13.15 IN (1) The aggregate amount beneficially owned by the Reporting Person consists of (i) 5,075,889 shares of voting common stock beneficially owned directly by the Reporting Person, consisting of (a) 1,999,296 shares of voting common stock and (b) 3,076,593 shares of voting common stock that are subject to options that are exercisable within 60 days of December 31, 2025, (ii) 142,553 shares of voting common stock held by Sidus Ventures, LLC, (iii) 423,655 shares of voting common stock held by Dolphin City Trust, (iv) 551,776 shares of voting common stock held by Blue Sky Trust and (v) 551,774 shares of voting common stock held by Brocade Trust. The Reporting Person is the manager of Sidus Ventures, LLC and may be deemed to have beneficial ownership over the securities held by Sidus Ventures, LLC. The Reporting Person is the beneficiary of Dolphin City Trust and may be deemed to have beneficial ownership over the securities held by Dolphin City Trust. The Reporting Person is the investment advisor for each of the Blue Sky Trust and the Brocade Trust, and may be deemed to have beneficial ownership over the securities held by each of the Blue Sky Trust and the Brocade Trust. (2) The percentage reported in row 11 is calculated in accordance with Rule 13d-3 based on the aggregate number of shares of common stock beneficially owned by the Reporting Person and an aggregate of 48,225,493 shares of voting common stock outstanding as of December 31, 2025, as reported by the Issuer to the Reporting Person, plus the number of shares of stock options held by the Reporting Person that are exercisable within 60 days of December 31, 2025, which are treated as converted into common stock only for the purpose of computing the percentage ownership of the Reporting Person. Prelude Therapeutics Inc 175 INNOVATION BOULEVARD, WILMINGTON, Delaware, 19805 Krishna Vaddi (the "Reporting Person") The address of the principal business office of the Reporting Person is: c/o Prelude Therapeutics Incorporated 175 Innovation Boulevard Wilmington, Delaware 19805 United States Y See Row 9 of cover page for each Reporting Person. See Row 11 of cover page for each Reporting Person. See Row 5 of cover page for each Reporting Person. See Row 6 of cover page for each Reporting Person. See Row 7 of cover page for each Reporting Person. See Row 8 of cover page for each Reporting Person. Y Y Y Y Y Y Vaddi Krishna /s/ Krishna Vaddi 02/13/2026